Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia

• Research type

  Research Study

• Full title

  An Exploratory, Multi-Center, Interventional, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients with Severe Community-Acquired Pneumonia.

• IRAS ID

  1008240

• Contact name

  Conrad Stroud

• Contact email

  conrad.stroud@micron-research.com

• Sponsor organisation

  Aptarion Biotech AG

• Eudract number

  2023-505985-28

• Clinicaltrials.gov Identifier

  NCT05962606

• Research summary

  The study will be conducted in multiple hospitals in different countries. Patients with Severe Community-Acquired Pneumonia will be given either AON-D21 or Placebo as an "add on" therapy in addition to the medicines their doctors would give as part of standard of care. The results will be used to check the safety and effectiveness of AON-D21.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  23/EM/0235

• Date of REC Opinion

  3 Nov 2023

• REC opinion

  Further Information Favourable Opinion